Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Aldeyra Therapeutics, Inc.
  6. Summary
    ALDX   US01438T1060

ALDEYRA THERAPEUTICS, INC.

(ALDX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
2.43(c) 2.49(c) 2.5(c) 2.64(c) 2.46(c) Last
821 081 518 530 474 230 780 201 629 667 Volume
-0.41% +2.47% +0.40% +5.60% -6.82% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -80,4 M - -
Net cash position 2022 130 M - -
P/E ratio 2022 -1,85x
Yield 2022 -
Sales 2023 28,8 M - -
Net income 2023 -91,6 M - -
Net cash position 2023 84,0 M - -
P/E ratio 2023 -1,79x
Yield 2023 -
Capitalization 143 M 143 M -
EV / Sales 2022 -
EV / Sales 2023 2,07x
Nbr of Employees 14
Free-Float 81,2%
More Financials
Company
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary... 
Read more
More about the company
Ratings of Aldeyra Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about ALDEYRA THERAPEUTICS, INC.
05/18Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading ..
BU
05/18ALDEYRA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/05ALDEYRA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/05TRANSCRIPT : Aldeyra Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05ALDEYRA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, ..
AQ
05/05Earnings Flash (ALDX) ALDEYRA THERAPEUTICS Posts Q1 Loss $-0.29
MT
05/05Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/05Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate ..
BU
05/04Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting
BU
04/29Omega Therapeutics Hires Aldeyra Therapeutics Chief Financial Officer Joshua Reed for S..
MT
04/28ALDEYRA THERAPEUTICS : Announces Chief Financial Officer Transition - Form 8-K
PU
04/28ALDEYRA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statemen..
AQ
04/28Aldeyra Therapeutics Announces Chief Financial Officer Transition
BU
04/28Aldeyra Therapeutics, Inc. Announces Executive Changes, Effective May 10, 2022
CI
04/28Aldeyra Therapeutics, Inc. Announces Management Changes, Effective May 10, 2022
CI
More news
News in other languages on ALDEYRA THERAPEUTICS, INC.
05/05Aldeyra Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 m..
04/29Omega Therapeutics engage Joshua Reed, directeur financier d'Aldeyra Therapeutics, pour..
04/28Aldeyra Therapeutics, Inc. annonce des changements au sein de sa direction, à compter d..
04/05Aldeyra Therapeutics achève de recruter des patients pour un essai de phase avancée sur..
04/05Aldeyra Therapeutics, Inc. annonce la fin du recrutement pour l'essai de phase 3 Tranqu..
More news
Analyst Recommendations on ALDEYRA THERAPEUTICS, INC.
More recommendations
Chart ALDEYRA THERAPEUTICS, INC.
Duration : Period :
Aldeyra Therapeutics, Inc. Technical Analysis Chart | ALDX | US01438T1060 | MarketScreener
Technical analysis trends ALDEYRA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 2,46 $
Average target price 20,89 $
Spread / Average Target 749%
EPS Revisions
Managers and Directors
Todd C. Brady President, Chief Executive Officer & Director
Bruce Greenberg Chief Financial Officer, Treasurer & VP-Finance
Richard H. Douglas Chairman
Martin Joseph Joyce Independent Director
Gary M. Phillips Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ALDEYRA THERAPEUTICS, INC.-38.50%143
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169